Pharmacologic treatment of alcohol use disorder rests on targeting distinct neurochemical mechanisms underlying dependence, withdrawal, and craving: aldehyde dehydrogenase inhibition to produce aversive conditioning, opioid receptor antagonism to blunt positive reinforcement, and modulation of glutamatergic/GABAergic imbalance to reduce negative reinforcement. This is a subdomain of clinical pharmacology and addiction medicine, situated within the broader framework of substance use disorder diagnosis (defined by tolerance, dependence, and withdrawal) and its downstream organ pathology. The theory connects biochemical mechanism of action to clinical indication, combining pharmacologic agents with non-pharmacologic (behavioral/support-group) therapy according to which reinforcement pathway each agent addresses.
Pharmacologic treatment of alcohol use disorder rests on targeting distinct neurochemical mechanisms underlying dependence, withdrawal, and craving: aldehyde dehydrogenase inhibition to produce avers…